How Ponaman Healthcare Consulting Approaches HRSA 340B Program Compliance: The Methodology Behind the Results

23 Jun How Ponaman Healthcare Consulting Approaches HRSA 340B Program Compliance: The Methodology Behind the Results

The 340B drug pricing program saves eligible healthcare organizations hundreds of millions of dollars annually — but according to HRSA’s own audit data, a significant portion of covered entities struggle to maintain the documentation standards required to keep those savings. For compliance officers and program managers, that gap between program participation and program defensibility is where careers, budgets, and patient care capacity are decided.

Direct Answer

Ponaman Healthcare Consulting approaches 340B compliance through a structured, four-phase methodology: program assessment, gap remediation, audit preparation, and continuous monitoring. Each phase uses defined compliance metrics and KPIs to identify risk before HRSA does. The result: 67% of clients complete audits with zero findings, and 80% of audit findings that do occur are successfully overturned on appeal.

Key Takeaways

• A 340B compliance program is only as strong as its weakest documentation point — most audit findings trace back to eligibility verification gaps, not intentional misuse.
• Ponaman Healthcare Consulting has supported 148 HRSA 340B audits, with 67% resulting in zero findings.
• When findings do occur, an 80% appeal success rate depends on having documentation infrastructure built before the audit notice arrives — not after.
• The most common compliance failure is treating 340B as a pharmacy benefit rather than a federal program with distinct patient definition, eligibility, and diversion requirements.
• Continuous monitoring between audits reduces finding severity more reliably than intensive pre-audit preparation alone.

What Does a 340B Audit Actually Measure — and Why Do So Many Organizations Get It Wrong?

Most organizations enter a HRSA 340B audit believing their exposure is limited to dispensing records. It isn’t.

HRSA audits evaluate four distinct compliance domains: patient eligibility and definition, covered outpatient drug qualification, duplicate discount prevention, and contract pharmacy oversight. Each domain has its own documentation standard. An organization can maintain flawless dispensing records and still receive findings because their patient definition policy doesn’t align with HRSA’s 2010 guidance on what constitutes a “patient” of the covered entity.

The real problem is definitional drift — the gradual divergence between how a program was originally set up and how it actually operates three or four years later as staff turns over, pharmacy contracts change, and EHR configurations shift.

This is not a failure of intent. It’s a failure of infrastructure. HRSA doesn’t audit intentions.

> A 340B program that runs well for two years without a compliance review isn’t a healthy program — it’s an unexamined one.

Why Does Compliance Drift Happen Even in Well-Managed Organizations?

The root cause isn’t negligence. It’s structural.

340B compliance sits at the intersection of pharmacy operations, clinical documentation, billing systems, and federal regulatory interpretation — four departments that rarely share a common reporting line. When HRSA updates guidance or a contract pharmacy changes its dispensing platform, the compliance impact doesn’t automatically surface in any single workflow. It accumulates silently.

Covered entities also face a specific challenge that other federal programs don’t impose: the 340B “patient definition” is not a static checklist. It requires ongoing clinical and administrative judgment about whether a patient’s relationship to the covered entity meets HRSA’s criteria at the point of dispensing. That judgment must be documented, consistent, and defensible — and it must survive staff transitions.

Most organizations don’t have a mechanism to detect when that judgment is drifting. They find out during an audit. Understanding how to structure compliance infrastructure before HRSA comes knocking is often the difference between an organization that finds out during an internal review and one that finds out from an auditor.

What Does the Ponaman Methodology Actually Do at Each Phase?

The Ponaman Healthcare Consulting methodology operates across four defined phases. Each phase has a specific function in the compliance lifecycle — not just a general purpose.

Phase 1: Baseline Assessment A structured review of the covered entity’s current program against HRSA’s audit protocol. This includes patient definition policy review, eligibility documentation sampling, contract pharmacy agreement analysis, and split-billing software configuration verification. The output is a prioritized risk register — not a general compliance score.

Phase 2: Gap Remediation Each identified gap receives a specific remediation plan with an assigned owner, timeline, and documentation standard. Ponaman’s team includes consultants, auditors, analysts, and medical and legal specialists — which matters because some gaps require policy revision, others require system reconfiguration, and others require legal review of contract pharmacy terms.

Phase 3: Audit Preparation When a HRSA audit notice arrives, the preparation window is narrow. Organizations that have completed Phases 1 and 2 enter this phase with documentation already organized. Those that haven’t face a compressed, reactive process that increases finding risk. Ponaman has supported 148 HRSA audits — the pattern is consistent: pre-built documentation infrastructure determines outcomes more than audit-week preparation does.

Phase 4: Continuous Monitoring Compliance is not a project with an end date. Ponaman implements KPI dashboards and periodic compliance reviews that flag eligibility drift, dispensing anomalies, and contract pharmacy performance issues between audit cycles. This is the mechanism behind the 67% zero-findings rate — not superior audit performance, but reduced audit exposure through ongoing monitoring.

> Most organizations treat 340B compliance as an audit problem. It’s actually a program management problem that audits expose.

The 340B Compliance Readiness Matrix: A Framework for Self-Assessment

The 340B Compliance Readiness Matrix is a structured self-assessment tool that maps an organization’s compliance posture across four risk dimensions against two variables: documentation completeness and policy currency.

Use this framework when: conducting an internal compliance review, onboarding a new 340B program manager, or preparing for a contract pharmacy renewal.

Do not use it as a substitute for an external compliance review when HRSA audit indicators are present (prior findings, recent contract pharmacy changes, EHR migration).

Any domain with two “No” responses represents high audit exposure. A single “No” in Policy Currency for duplicate discount prevention is a critical finding risk, because HRSA’s audit protocol specifically targets this domain in contract pharmacy arrangements.

What Does a Real Remediation Timeline Look Like?

A community health center with a multi-site contract pharmacy arrangement and three years without a formal compliance review engaged Ponaman Healthcare Consulting after receiving a HRSA audit notification. The initial assessment identified gaps across patient definition documentation and contract pharmacy oversight — two of the four highest-risk audit domains.

Over an 11-week engagement prior to the audit, the team remediated documentation gaps, revised the patient definition policy to align with current HRSA guidance, and reorganized the contract pharmacy audit trail. The audit resulted in two minor findings — a 50% reduction from the organization’s prior audit cycle. Both findings were successfully appealed.

The mechanism that made the difference wasn’t the audit preparation itself. It was having a team that understood which documentation gaps HRSA auditors weight most heavily — and addressing those first under time pressure. What real ROI from 340B consulting looks like — and what drives the difference often comes down to exactly this: the ability to prioritize the right gaps under a compressed timeline.

How Does Working with a Specialized Consultant Compare to Managing 340B Compliance In-House?

This is a genuine tradeoff, not a rhetorical one.

In-house management works when an organization has a dedicated, experienced 340B program manager, stable pharmacy operations, and a consistent compliance review cadence. It breaks down during staff transitions, program expansions, or when HRSA audit patterns shift — which they do. A closer look at 340B consulting vs. the alternatives clarifies when external support adds the most value and when internal capacity is genuinely sufficient.

Who Is This Approach Not Right For?

Honest answer: not every organization needs the same level of engagement.

If your covered entity has a fully staffed 340B compliance team, has completed a formal compliance review within the past 12 months, and has no contract pharmacy arrangements, a full-scope consulting engagement may not be your highest-value use of resources.

Ponaman Healthcare Consulting is specifically built for organizations navigating active audit risk, implementing new contract pharmacy arrangements, expanding to new sites, or recovering from prior audit findings. The methodology is designed for complexity — it’s most valuable when the compliance environment is changing or when prior reviews have identified unresolved gaps.

This approach also requires organizational participation. Documentation remediation depends on access to EHR data, pharmacy records, and billing systems. Engagements that stall on internal data access produce slower results.

Frequently Asked Questions

How long does a typical 340B compliance review take before a HRSA audit? A baseline compliance assessment typically takes three to six weeks depending on program complexity and data availability. Organizations that receive a HRSA audit notice should begin immediately — the preparation window is usually 60 to 90 days, and documentation gaps identified late in that window are significantly harder to remediate.

What’s the most common reason organizations receive audit findings? Patient definition documentation is consistently the highest-frequency finding category. The issue is usually not that patients are ineligible — it’s that the documentation connecting the patient’s clinical relationship to the covered entity isn’t organized in a way that satisfies HRSA’s audit protocol.

Can audit findings actually be overturned after they’re issued? Yes — and more often than most organizations expect. Ponaman Healthcare Consulting’s 80% appeal success rate reflects a specific process: findings are analyzed for documentation gaps versus policy violations, and appeals are built around the documentation record rather than procedural arguments. Not all findings are appealable, but many that appear final at issuance are not.

What happens if we’ve had prior audit findings — does that increase our risk in future audits? Prior findings do create elevated scrutiny in subsequent HRSA audits. The more important variable is whether the underlying gap that produced the finding has been genuinely remediated — not just acknowledged. Organizations with prior findings that haven’t completed a formal remediation review are at higher risk of repeat findings in the same domain.

How does Ponaman handle contract pharmacy compliance specifically? Contract pharmacy arrangements are reviewed against HRSA’s contract pharmacy guidance, the specific terms of each pharmacy agreement, and the covered entity’s internal oversight documentation. This includes dispensing data analysis, duplicate discount prevention verification, and policy review — because contract pharmacy compliance failures are among the most common and most consequential audit findings.

Is 340B consulting worth the cost for smaller community health centers? The cost-benefit calculation depends on program savings volume and audit risk, not organization size. A community health center generating $500,000 annually in 340B savings that receives a finding requiring repayment faces a loss that typically exceeds the cost of a compliance engagement. Smaller organizations often have the most to lose from a single audit cycle.

What should we do right now if we haven’t had a compliance review in over a year? Start with a self-assessment using the four compliance domains — patient definition, covered outpatient drug qualification, duplicate discount prevention, and contract pharmacy oversight — and identify where documentation is incomplete or policies haven’t been updated since your last HRSA guidance review. If you find gaps in more than one domain, a formal external review is the appropriate next step before those gaps surface in an audit.

If Your Last Compliance Review Was More Than 12 Months Ago, This Is the Moment to Act

The organizations that arrive at a HRSA audit with zero findings didn’t get lucky. They built documentation infrastructure before the audit notice arrived — and they had a team that knew which gaps HRSA auditors weight most heavily.

If you’re managing a 340B program with unreviewed contract pharmacy arrangements, staff turnover in your compliance function, or a prior audit cycle with findings, the gap between where your documentation is and where it needs to be is growing — not staying still.

Contact Ponaman Healthcare Consulting to schedule a compliance assessment. Not a general conversation — a structured review of your program against the four HRSA audit domains, with a prioritized risk register you can act on.

That’s the starting point. Everything else follows from knowing exactly where you stand.

References

HRSA — Health Resources and Services Administration; administers the 340B Drug Pricing Program and publishes audit protocols, program guidance, and covered entity compliance requirements at hrsa.gov.

HRSA Office of Pharmacy Affairs — Oversees 340B program compliance, issues audit findings, and publishes guidance documents including the 2010 patient definition guidance referenced in covered entity compliance reviews.